Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Invest New Drugs
; 41(2): 350-355, 2023 04.
Article
em En
| MEDLINE
| ID: mdl-37004644
ABSTRACT
Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Síndrome de Sézary
Limite:
Humans
Idioma:
En
Revista:
Invest New Drugs
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos